CANCER:

Giant Cell Tumor of Bone

No biomarker No biomarker	Giant Cell Tumor of Bone Giant Cell Tumor of Bone	denosumab Sensitive: A1 - Approval
No biomarker No biomarker	Tenosynovial Giant Cell Tumor Tenosynovial Giant Cell Tumor	pexidartinib Sensitive: A1 - Approval
No biomarker No biomarker	Chordoma Chordoma	sorafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Chordoma Chordoma	dasatinib Sensitive: A2 - Guideline
No biomarker No biomarker	Chordoma Chordoma	YD312 Sensitive: A2 - Guideline
No biomarker No biomarker	Chordoma Chordoma	sunitinib Sensitive: A2 - Guideline
No biomarker No biomarker	Chordoma Chordoma	erlotinib Sensitive: A2 - Guideline
TMB-H TMB-H	Chordoma Chordoma	pembrolizumab Sensitive: A2 - Guideline
EGFR expression EGFR expression	Chordoma Chordoma	lapatinib Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Chordoma Chordoma	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Chordoma Chordoma	imatinib Sensitive: A2 - Guideline
SMARCB1 negative SMARCB1 negative	Chordoma Chordoma	tazemetostat Sensitive: C2 – Inclusion Criteria
PIK3CA amplification PIK3CA amplification	Chordoma Chordoma	everolimus Sensitive: C3 – Early Trials
PIK3CA M1043I PIK3CA M1043I	Chordoma Chordoma	everolimus Sensitive: C3 – Early Trials
PTEN deletion PTEN deletion	Chordoma Chordoma	PDGFR inhibitor Resistant: C4 – Case Studies
PTEN deletion PTEN deletion	Chordoma Chordoma	PDGFR inhibitor + HDAC inhibitor Sensitive: C4 – Case Studies
H3F3A mutation + ARID2 mutation H3F3A mutation + ARID2 mutation	Giant Cell Tumor of Bone Giant Cell Tumor of Bone	denosumab Resistant: C4 – Case Studies
COL6A3-CSF1 fusion COL6A3-CSF1 fusion	Tenosynovial Giant Cell Tumor Tenosynovial Giant Cell Tumor	gefitinib + mitoxantrone Sensitive: C4 – Case Studies
AXL underexpression AXL underexpression	Chordoma Chordoma	afatinib Sensitive: D – Preclinical
STK33 underexpression STK33 underexpression	Chordoma Chordoma	afatinib Sensitive: D – Preclinical

Giant Cell Tumor of Bone

Associations(20)

Associations
(20)